Patents Assigned to Metabolomic Technologies Inc.
  • Publication number: 20240084394
    Abstract: The invention relates to methods and compositions for detecting colorectal cancer and colorectal polyps by measurement of metabolites in bodily fluids such as urine, including diacetylspermine and kynurenine.
    Type: Application
    Filed: November 3, 2023
    Publication date: March 14, 2024
    Applicant: Metabolomic Technologies Inc.
    Inventors: Lu DENG, David Chang
  • Patent number: 11840720
    Abstract: The invention relates to methods and compositions for detecting colorectal cancer and colorectal polyps by measurement of metabolites in bodily fluids such as urine, including diacetylspermine and kynurenine.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: December 12, 2023
    Assignee: Metabolomic Technologies Inc.
    Inventors: Lu Deng, David Chang
  • Publication number: 20210189499
    Abstract: The invention relates to methods and compositions for detecting colorectal cancer and colorectal polyps by measurement of metabolites in bodily fluids such as urine, including diacetylspermine and kynurenine.
    Type: Application
    Filed: December 23, 2019
    Publication date: June 24, 2021
    Applicant: Metabolomic Technologies Inc.
    Inventors: Lu DENG, David CHANG
  • Patent number: 9442121
    Abstract: A method for treating depression using a biomarker includes measuring a level of phosphoethanolamine in a blood sample collected from a subject, comparing the level of phosphoethanolamine in the blood sample with a predetermined threshold, in response to the level of phosphoethanolamine in the blood sample being below the predetermined threshold, determining that the subject requires a treatment for depression, and treating the subject determined to suffer from depression.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: September 13, 2016
    Assignees: Human Metabolome Technologies, Inc.
    Inventors: Noriyuki Kawamura, Kosaku Shinoda, Yoshiaki Ohashi, Takamasa Ishikawa, Hajime Sato
  • Patent number: 8951739
    Abstract: Provided is a method for using low molecular weight compounds found in the body as a biomarker for diagnosing depression. Specifically, more than one compound selected from a group comprising the following are used: ADP-ribose, ATP, ADP, AMP, serotonin, tryptophan, kynurenine, SDMA (symmetrical dimethylarginine), threonine, glyceric acid, serine, N-acetylaspartic acid, glutamic acid, trigonelline, creatine, 2-methylserine, sphingosine, homovanillic acid, piperidine, sulfoxidized methionine, pipecolic acid, sphinganine, gamma-butyrobetaine, guanidinoacetic acid, isobutyric acid, creatinine, sarcosine, 3-methylbutyric acid, nicotinamide, betaine, ornithine, carnitine, ethanolamine, phosphoethanolamine, taurine, hypotaurine, aspartic acid, methionine, and tyrosine.
    Type: Grant
    Filed: August 12, 2010
    Date of Patent: February 10, 2015
    Assignee: Human Metabolome Technologies Inc.
    Inventors: Noriyuki Kawamura, Kosaku Shinoda, Yoshiaki Ohashi, Takamasa Ishikawa, Hajime Sato
  • Patent number: 8927221
    Abstract: The present invention relates to novel diagnostic markers for kidney disease and the use thereof.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: January 6, 2015
    Assignees: Sysmex Corporation, Human Metabolome Technologies, Inc.
    Inventors: Hajime Sato, Yoshiaki Ohashi, Kazunori Sasaki, Kouzou Suto, Yasuhiro Otomo